Company: SGBAF
Filing Date: 2025-04-01
Form Type: DRS/A
Source: 0000950123-25-003272
Chunk: 365

Company: SES S.A.
Filing Date: 2025-04-01
Form: DRS/A
Chunk 365
---
 the European Commission has awarded the SpaceRISE consortium the contract to design, deliver, and operate IRIS² for the next 12 years (see Note 1). The amount of EUR 300.0 million (2023: EUR nil) represents the funds received from European Commission in relation to this programme, representing initial funding for programme costs arising in the first year of the programme for both SES ASTRA S.A. and other consortium members and subcontractors. Note 30—Other long-term liabilities

| € million                             |     | 2024 |    |     | 2023 |    |
| Employee benefits obligations         |     |      | 14 |     |      | 13 |
| Payments received in advance          |     |      | 23 |     |      | 47 |
| Other long-term financial liabilities |     |      | 18 |     |      | 23 |
| Total                                 |     |      | 55 |     |      | 83 |

Employee benefits obligations In the Group’s US operations certain employees benefit from an externally insured post-retirement health benefit plan. As of December 31, 2024, accrued premiums of EUR 7 million (2023: EUR 6 million) are included in this position. There were no contributions made in 2024 to Group pension schemes (2023: nil). In addition, certain employees of the US operations benefit from defined contribution pension plans. A liability of EUR 8 million has been recognized as of December 31, 2024 (2023: EUR 10 million) in this respect, out of which EUR 0 million is included under ‘Trade and other payables’ (2023: EUR 2 million). Payments received in advance In the framework of receivables securitization transactions completed in June 2019 the Group received a net cash amount of EUR 59 million, from the financial institution as advance settlement of future receivables arising between 2022 and 2024 under contracts with a specific customer. The entire outstanding balance of EUR 25 million as of December 31, 2023 was repaid to the financial institution in January 2024. F-85

Confidential Treatment Requested by SES Pursuant to 17 C.F.R. Section 200.83 Consolidated financial statements as of and for the years ended December 31, 2024, December 31, 2023 and December 31, 2022 In June 2022, the Company